University of Cambridge and Cancer Research UK Professor of Biology, and Head of Cancer Research UK Laboratories at the Gurdon Institute
Steve Jackson FRS, FMedSci is University of Cambridge and Cancer Research UK Professor of Biology, and Head of Cancer Research UK Laboratories at the Gurdon Institute. His research (publication h-index 128, citations >71,000; Google Scholar) has identified key principles by which cells respond to and repair DNA damage, and helped define how their dysfunction yields cancer and other age-related diseases. Steve is a fellow of the Royal Society and has received many prizes, including the 2015 Gagna and van Heck Prize for Medicine, the 2016 King Faisal International Prize for Science, the 2016 AH. Heineken Prize for Medicine, and the 2019 Fondation ARC Léopold Griffuel Award for Translational and Clinical Research.
To translate his academic work towards patient benefit, in 1997 Steve founded the drug-discovery company KuDOSPharmaceuticals Ltd., then served as its part-time Chief Scientific Officer (CSO) until and after its acquisition by AstraZeneca. Several KuDOS-derived drugs are in clinical trials, with the most advanced, the PARP inhibitor olaparib/LynparzaTM, being a marketed drug for ovarian and breast cancers worldwide. In 2010, Steve founded Mission Therapeutics Ltd. (Babraham, Cambridge) to exploit advances in protein ubiquitylation and deubiquitylation to derive new medicines, and until recently served as its part-time CSO. Steve’s science also underpinned the foundation of Carrick Therapeutics Ltd., for which he now serves as a scientific advisor. Steve is a Science Partner of Ahren Innovation Capital, and serves as part-time Chief Executive Officer for Adrestia Therapeutics Ltd., a company that he co-founded in 2018. Steve’s academic laboratory is currently further defining mechanisms of DNA repair and associated processes, with a view to delivering new biological insights and identifying therapeutic opportunities for cancer and various other diseases.
(+44) 1223 496 000
Babraham Bioscience Technologies Ltd
Babraham Research Campus
CB22 3AT, United Kingdom
01223 813 557